摘要
目的探讨舍曲林合并齐拉西酮治疗伴躯体症状抑郁症的疗效及安全性。方法将38例服用舍曲林联合小剂量齐拉西酮患者(简称研究组)与40例单用舍曲林(简称对照组),从药物的起效时间、症状的改善时间,治疗1、2、4及8周时HAMA、TESS分值评定疗效和不良反应,并随访1年,观察1年内的复发率。结果治疗后两组HAMD评分较治疗前均有显著下降(P均<0.01),两组比较差异有显著性(P<0.05),研究组在治疗1周末评分差异已有显著性(P<0.05),对照组在治疗2周末差异才有显著性(P<0.01),研究组HAMD因子分在焦虑/躯体化方面下降较单用组快。两组TESS评分及1年内复发率差异无显著性(P>0.05)。结论舍曲林合并齐拉西酮治疗伴躯体症状抑郁症疗效较好,且较安全。
OBJECTIVE To explore the efficacy and safety of depression with somatic symptoms by Sertraline combined with small dosage of Ziprasidone.METHODS 38 patients take Sertraline combined with small dosage of Ziprasidone are defined as the study group and 40 patients take Sertraline are defined as the control group.The time of efficacy and improvement,HAMD scores after 1,2,4,8weeks,TESS scores,compliance and the recurrence rate of depression within 1 year.RESULTS After 8 weeks treatment both groups have significant reduction in HAMD scores（P0.01）.There is significant difference between two groups（P0.05）.study group showed significant decrease at the first weekend（P0.05）,while the control group showed significant decrease after two weeks（P0.01）.Anxiety,somatization scores of HAMD got downe rapidly in the study group.The two groups showed no significant differences in TESS scores and the recurrence rate within 1year（P0.05）.CONCLUSION It was indicated that the efficacy to choice of Sertraline combined with small dosage of Ziprasidone could be better than Sertraline only when treating depression with somatic symptoms.
出处
《海峡药学》
2011年第6期84-87,共4页
Strait Pharmaceutical Journal
关键词
齐拉西酮
舍曲林
躯体症状
抑郁症
Ziprasidone
Sertraline
Somatic symptoms
Depression
